Third Harmonic Bio — Investor Presentation (January 2024)
18 slides from Third Harmonic Bio's investor presentation, Jan 4, 2024
Slide 1: Advancing the next wave of focused medicine for inflammatory diseases
Exhibit 99.2 On advancing the next wave of FOCUSED medicine for inflammatory diseases JANUARY 2024 ©2024 THIRD HARMONIC BIO
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. Any statements made in this presentation that are not statements of historical fact, inclu
Slide 3: Recent Highlights
Recent Highlights Appointed Chris Murphy as Chief Financial and Business Officer IND-enabling toxicology studies of THB335 nearing completion Completed Pre-IND interaction with the U.S. FDA On track to file a U.S. IND and initiate a Phase 1 study of THB335 during 1H’24 Strong financial position with
Slide 4: Focused on KIT Inhibition to Treat Mast Cell-Mediated Inflammatory Diseases
Third Harmonic Bio: Focused on KIT Inhibition to Treat Mast Cell-Mediated Inflammatory Diseases LARGE ESTABLISHED KIT: A NOVEL, SELECTIVE MARKETS WITH HIGH CLINICALLY VALIDATED “PIPELINE-IN-A-TARGET” ORAL KIT UNMET NEED TARGET INHIBITORS POTENTIAL Mast Cell-Mediated Diseases Millions of patients liv
Slide 5: Mast Cells are a Fulcrum of Inflammation
Mast Cells are a Fulcrum of Inflammation Current therapeutic approaches are mechanistically limited MANY ACTIVATORS MAST CELL MANY MEDIATORS IgE Antigen Receptor-binding agonists Pre-formed mediators Omalizumab IgE Histamine Anti-histamines Receptor Complement IL-4, IL-13 Dupilumab Neuropeptides TNF
Slide 6: KIT is the Master Regulator of Mast Cell Function and Survival
KIT is the Master Regulator of Mast Cell Function and Survival Intracellular small molecule approach to KIT inhibition offers multiple potential therapeutic advantages KIT SCF dimer • Master regulator of mast cell proliferation, migration, activation and survival KIT receptor • KIT inhibition drives
Slide 7: Clinical results from first generation THB001 oral KIT inhibitor
Clinical results from first generation THB001 oral KIT inhibitor 7
Slide 8: First-Generation Product Candidate: THB001
First-Generation Product Candidate: THB001 Early results support the potential of oral KIT inhibition and inform next-gen development THB001 PHASE 1 STUDY RESULTS: • THB001 demonstrated high potency and Rapid and dose-dependent drops in serum tryptase selectivity for KIT à mast cell depletion and di
Slide 9: THB001 Discontinued Phase 1b Chronic Inducible Urticaria Study Overview
1 THB001 Discontinued Phase 1b Chronic Inducible Urticaria Study Overview Dose escalation study designed to interrogate potential for therapeutic index optimization DESIGN AND OBJECTIVES STUDY SCHEMATIC • 3 doses (1:1:1) of THB001 (total N=30) for 12 weeks • Pharmacokinetics and serum tryptase level
Slide 10: THB001 in Phase 1b CINDU Study Safety Summary
THB001 in Phase 1b CINDU Study Safety Summary THB001 HEMATOLOGY Hemoglobin and neutrophil count by subject over time Hemoglobin (g/dL) 16 • No serious or severe adverse events (AEs) ULN Baseline 15 • Two moderate AEs of transaminitis which resolved 14 13 at weeks 17 and 25 of follow-up LLN 12 • All
Slide 11: THB001 Generated Responses at Lowest Planned Dose in Phase 1b Study
Serum Tryptase µg/L THB001 Generated Responses at Lowest Planned Dose in Phase 1b Study 4 of 5 subjects reached partial (n=2) or complete (n=2) Critical Temperature Threshold responses SUBJECT 1 >> SUBJECT 2>> SUBJECT 3>> SUBJECT 4 >> SUBJECT 5 >> PARTIAL RESPONSE PARTIAL RESPONSE NO RESPONSE COMPLE
Slide 12: Understanding Hepatic Effects of THB001
Understanding Hepatic Effects of THB001 Mechanistic understanding allows for differentiation of next-generation candidate Conducted studies characterizing liver metabolism and phenotypic effects of THB001 Employed a comprehensive approach: • Assessed evidence for off-target biology liabilities • Cha
Slide 13: THB001 Shows Evidence for Formation of a Toxic Reactive Metabolite
THB001 Shows Evidence for Formation of a Toxic Reactive Metabolite Three findings from mechanistic studies provide potential basis for observed transaminitis 14 [ C] THB001 COVALENT PROTEIN ADDUCT FORMATION in Human Liver Microsomes • Studies identify major metabolite in human plasma which is formed
Slide 14: Next generation oral KIT inhibitor THB335
Next generation oral KIT inhibitor THB335 14
Slide 15: THB335 Potent and Selective Small Molecule KIT Inhibitor
THB335 Potent and Selective Small Molecule KIT Inhibitor Maintained kinase inhibition profile to THB001 but lacking evidence for reactive metabolite formation COMPARISON OF KEY KINASE AND METABOLIC PATHWAY PARAMETERS THB335 KinomeScan THB001 THB335 467 Assays Tested 8 Interactions Mapped KIT IC 23 n
Slide 16: THB335 Demonstrated Favorable Nonclinical Profile
THB335 Demonstrated Favorable Nonclinical Profile THB335 MAST CELL DEPLETION THB335 PK IN NONCLINICAL MODEL 14-day non-GLP toxicology study (oral administration) Skin (Ear) Intestine (jejunum) Lung (pleural) 10000 p<0.001 p<0.001 p<0.001 70 300 100 60 250 1000 80 50 200 60 40 150 100 30 40 100 20 20
Slide 17: Third Harmonic Bio Next Steps
Third Harmonic Bio Next Steps Advancing THB335 back toward the clinic with a longer-term view toward franchise expansion • THB335 U.S. IND filing and clinical trial initiation on track for 1H’24 • Targeting chronic spontaneous urticaria as initial clinical indication • Planned expansion into additio
Slide 18: Advancing the next wave of medicine for inflammatory diseases
The next wave of medicine for ADVANCING inflammatory diseases 18
Third Harmonic Bio — Investor Presentation (January 2024) on 6ix